PROPRANOLOL
Primary Peritoneal Serous Adenocarcinoma
M.D. Anderson Cancer CenterSmall moleculeEarly Phase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
32 Active assets in the Primary Peritoneal Serous Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BBB |
Olaparib NRG Oncology | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2/3 | BB |
Letrozole NRG Oncology | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 45 →
Same molecule, other indications
PROPRANOLOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →